Alterity Therapeutics (ATHE) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.
The result was achieved at the 50 mg dose at week 52 when compared with placebo, Alterity said.
The company also said that ATH434 was well-tolerated, with no reported serious adverse events.
Price: 5.48, Change: +2.49, Percent Change: +83.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.